New
HealthMore in Health→
Perioperative Atezolizumab More Than Doubles Event-Free Survival in Resectable NSCLC
Key Takeaways
- Median event-free survival reached 62.8 months with perioperative atezolizumab plus platinum-based chemotherapy versus 34.9 months with chemotherapy alone.
- Pathological complete response was 29.6% versus 8.5%, and major pathological response was 53.6% versus 24.4%.
- The Phase III IMpower030 trial did not meet its predefined statistical significance threshold, though investigators called the improvements clinically meaningful.
- Benefits appeared consistent across independent review facility-assessed and investigator-assessed event-free survival, disease-free survival and overall survival.
DE
DT Editorial Team··via medicalxpress.com